Allogene's CAR T therapy shows 31% response rate in kidney cancer

July 15, 2026 8:30 AM

Allogene Therapeutics (Nasdaq: ALLO) announced the publication of complete Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found